How to predict and prevent the immunogenicity of therapeutic proteins

Biotechnology Annual Review

Volumn 14, Issue , 2008, Pages 191-202

  Schellekens, Huub ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

immunogenicity; prediction; prevention; therapeutic proteins

Indexed keywords

ALPHA2A INTERFERON; ANTIBODY; ASPARAGINASE; ERYTHROPOIETIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH HORMONE; IMMUNOSUPPRESSIVE AGENT; INSULIN; INTERFERON; LIPOSOME; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; METHOTREXATE; MONOCLONAL ANTIBODY; PROTEIN; STREPTOKINASE;

ANAPHYLAXIS; DRUG CONTAMINATION; DRUG FORMULATION; DRUG IMPURITY; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PROTEIN AGGREGATION; REVIEW; SERUM SICKNESS;

ANIMALS; COMPUTER SIMULATION; HUMANS; IMMUNITY, NATURAL; IMMUNOGENETICS; MODELS, GENETIC; MODELS, IMMUNOLOGICAL; PROTEINS;

EID: 46149124807     PISSN: 13872656     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1387-2656(08)00007-0     Document Type: Review

References (24)

1. Walsh G. Pharmaceutical biotechnology products approved within the European Union. Eur J Pharm Biopharm 55 (2003) 3-10
2. Moore W.V., and Leppert P. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinol Metab 51 (1980) 691-697
3. White II G.C., Kempton C.L., Grimsley A., Nielsen B., and Roberts H.R. Cellular immune responses in hemophilia: why do inhibitors develop in some, but not all hemophiliacs?. J Thromb Haemost 3 8 (2005) 1676-1681 Review
4. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 24 11 (2002) 1720-1740
5. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 1 6 (2002) 457-462
6. Schellekens H., Ryff J.C., and van der Meide P.H. Assays for antibodies to human interferon-alpha: the need for standardization. J Interferon Cytokine Res 17 Suppl 1 (1997) S5-S8
7. Neyer L., Hiller J., Gish K., Keller S., and Caras I. Confirming human antibody responses to a therapeutic monoclonal antibody using a statistical approach. J Immunol Methods 315 1-2 (2006) 80-87 Epub Aug 7
8. Geng D., Shankar G., Schantz A., Rajadhyaksha M., Davis H., and Wagner C. Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies. J Pharm Biomed Anal 39 3-4 (2005) 364-375
9. Mire-Sluis A.R., Barrett Y.C., Devanarayan V., Koren E., Liu H., Maia M., Parish T., Scott G., Shankar G., Shores E., Swanson S.J., Taniguchi G., Wierda D., and Zuckerman L.A. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 289 (2004) 1-16
10. Bachmann M.F., Rohrer U.H., Kundig T.M., Burki K., Hengartner H., and Zinkernagel R.M. The influence of antigen organization on B cell responsiveness. Science 262 (1993) 1448-1451
11. Chakerian B., Lenz P., Lowy D.R., and Schiller J.T. Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol 169 (2002) 6120-6126
12. Fehr T., Bachmann M.F., Bucher E., Kalinke U., Di Padova F.E., Lang A.B., Hengartner H., and Zinkernagel R.M. Role of repetitive antigen patterns for induction of antibodies against antibodies. J Exp Med 185 (1997) 1785-1792
13. Veronese F.M., and Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 10 21 (2005) 1451-1458
14. Vadhan-Raj S. Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia. Semin Hematol 37 2 Suppl 4 (2000) 28-34
15. Ottesen J.L., Nilsson P., Jami J., Weilguny D., Duhrkop M., Bucchini D., Havelund S., and Fogh J.M. The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia 37 (1994) 1178-1185
16. Hermeling S., Schellekens H., Maas C., Gebbink M.F., Crommelin D.J., and Jiskoot W. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J Pharm Sci 95 5 (2006) 1084-1096
17. Hochuli E. Interferon immunogenicity: technical evaluation of interferon-alpha 2a. J Interferon Cytokine Res 17 Suppl 1 (1997) S15-S21
18. Rosenberg A.S. Effects of protein aggregates: an immunologic perspective. AAPS J 8 3 (2006) E501-E507
19. Casadevall N., Nataf J., Viron B., Kolta A., Kiladjian J.J., Martin-Dupont P., Michaud P.T., Ugo V., Teyssandier I., Varet B., and Mayeux P. Pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. New Engl J Med 346 (2002) 469-475
20. Braun K.L., Labow M.A., and Alsenz J. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res 14 (1997) 1472-1478
21. Hermeling S., Jiskoot W., Crommelin D., Bornaes C., and Schellekens H. Development of a transgenic mouse model immune tolerant for human interferon Beta. Pharm Res 22 6 (2005) 847-851 Epub Jun 8
22. Stewart T.A., Hollingshead P.G., Pitts S.L., Chang R., Martin L.E., and Oakley H. Transgenic mice as a model to test the immunogenicity of proteins altered by site-specific mutagenesis. Mol Biol Med 6 (1989) 275-281
23. Pendley C., Schantz A., and Wagner C. Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther 5 (2003) 172-179
24. Presta L.G. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 58 5-6 (2006) 640-656 Epub May 23